Home

Submit Your Email now, and get
Our Latest update

FUNDRAISING

Maintenance, engineering and sustaining capital service provider Tasmea Limited ASX Listing IPO Oil and Gas Exploration D3 Energy Limited BlinkLab was incorporated on 17 August 2021 for the purpose of accelerating the development and commercialisation of intellectual property developed at Princeton University relating to smartphone-neurobehavioral testing (Licenced IP). BlinkLab has the exclusive worldwide licence to commercialise the Licenced IP and has developed a smartphone-based application with an e-platform that serves as a medical device to perform neurometric tests to aid in the diagnosis of autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), schizophrenia and other neurodevelopmental conditions (BlinkLab Device). The tests include, but are not limited to, eyeblink conditioning (EBC), prepulse inhibition of acoustic startle (PPI) and habituation of eye blink response which serve as biomarkers for neurological and psychiatric disorders (BlinkLab Tests). The results from the BlinkLab Tests are recorded by smartphone and uploaded to BlinkLab’s confidential and secure online platform where the data is analysed using machine learning (ML). Upon admission, the primary focus of BlinkLab will be to complete the necessary regulatory clinical studies and obtain the necessary regulatory approvals (that being FDA approval in the US and CE Mark in Europe) to bring the BlinkLab Device to market initially as a diagnostic tool for ASD. Blinklab Limited IPO 1111 TestS NSX N/A this is a t test gold test Test Fundraising Dec 15 IPO N/A rights issue abc Rights Issue The Company is a global Integration Platform as a Service (iPaaS) and cloud-based platform as a service for the financial services industry and particularly for the non-bank lending market. It provides software integration, automation and workflow solutions that addresses each processing phase of assets for financial services organisations. Test Table

AI Membership